Yunpeng Yang

9.3k total citations · 1 hit paper
220 papers, 4.1k citations indexed

About

Yunpeng Yang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yunpeng Yang has authored 220 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Oncology, 112 papers in Pulmonary and Respiratory Medicine and 56 papers in Molecular Biology. Recurrent topics in Yunpeng Yang's work include Lung Cancer Treatments and Mutations (97 papers), Lung Cancer Research Studies (49 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Yunpeng Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (97 papers), Lung Cancer Research Studies (49 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Yunpeng Yang collaborates with scholars based in China, United States and Canada. Yunpeng Yang's co-authors include Wenfeng Fang, Yan Huang, Hongyun Zhao, Yuxiang Ma, Shaodong Hong, Yuanyuan Zhao, Li Zhang, Ting Zhou, Jianhua Zhan and Xue Hou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Yunpeng Yang

208 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

2018 326 citations Wenfeng Fang, Yunpeng Yang et al. profile →

Peers

Countries citing papers authored by Yunpeng Yang

Since Specialization

Citations

This map shows the geographic impact of Yunpeng Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yunpeng Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yunpeng Yang more than expected).

Fields of papers citing papers by Yunpeng Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yunpeng Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yunpeng Yang. The network helps show where Yunpeng Yang may publish in the future.

Co-authorship network of co-authors of Yunpeng Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Yunpeng Yang. A scholar is included among the top collaborators of Yunpeng Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yunpeng Yang. Yunpeng Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Smart-SNPer: Automated crRNA design for ultrasensitive RPA-Cas12a SNP detection 2025 ·Biosensors and Bioelectronics ·(unknown), (unknown), Wang Lv, Feng Chen, Tianyi Tan, (unknown), (unknown), Yunpeng Yang, (unknown), (unknown), (unknown), Lijing Hao, (unknown), (unknown), (unknown), (unknown), Tao Chen, Lizhen Huang	0
2	Survey of Blockchain‐Based Industrial Metaverse in SMMEs 2025 ·Transactions on Emerging Telecommunications Technologies ·(unknown), Junbiao Wang, (unknown), (unknown), Yi Zhou, Qingqiang Tu, Jingjing Zhu, Yunpeng Yang	0
3	Improving the growth and intestinal colonization of Escherichia coli Nissle 1917 by strengthening its oligopeptides importation ability 2024 ·Metabolic Engineering ·(unknown), (unknown), (unknown), Yufei Huang, Yanhong Nie, Yunpeng Yang	2
4	Remodeling the tumor-immune microenvironment by anti-CTLA4 blockade enhanced subsequent anti-PD-1 efficacy in advanced nasopharyngeal carcinoma 2024 ·npj Precision Oncology ·Yuxiang Ma, Huaqiang Zhou, Fan Luo, Yang Zhang, Changbin Zhu, Weiwei Li, (unknown), (unknown), Jinhui Xue, Yuanyuan Zhao, Wenfeng Fang, Yunpeng Yang, Yan Huang, (unknown), Hongyun Zhao	6
5	A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). 2024 ·Journal of Clinical Oncology ·Hui Liu, Bo Qiu, Yuanyuan Zhao, Wenzhuo He, Weineng Feng, (unknown), Jun Jia, Fanjun Meng, (unknown), (unknown), JinYu Guo, (unknown), Suping Guo, (unknown), (unknown), Jibin Li, Yunpeng Yang, Liangping Xia, (unknown)	3
6	Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study 2024 ·Cancer Research ·Yunpeng Yang, Yuanyuan Zhao, Wenfeng Fang, Yan Huang, Yaxiong Zhang, Yi Ba, Zhen Wang, Chao Deng, Desheng Hu, W. Wang, Guiling Li, Suxia Luo, Zhichao Fu, (unknown), Huili Wang, Shiwei Zhao, Tao Li, Charles L. Cai, Li Zhang	1
7	HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype 2024 ·Journal for ImmunoTherapy of Cancer ·Fan Luo, Jiaxin Cao, (unknown), (unknown), (unknown), Xue Bai, Wenjuan Ma, (unknown), Ting Zhou, Jianhua Zhan, Yan Huang, Yunpeng Yang, (unknown), (unknown)	3
8	C1q/tumor necrosis factor-related protein-9 exerts antioxidant and anti-inflammatory effects on oxygen-glucose deprivation/reoxygenation-stimulated neurons by modulating the Akt-GSK-3β-Nrf2 cascade via AdipoR1 2023 ·International Immunopharmacology ·Jing Wang, (unknown), Yunpeng Yang, Yu Li	3
9	74P A single-center, phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC) 2023 ·Immuno-Oncology Technology ·Wenfeng Fang, Yunpeng Yang, Yan Huang, (unknown), Yaojun Zhang, Ting Zhou, (unknown), Shen Zhao, Yuxiang Ma, Shaodong Hong, Hongyun Zhao, Li Zhang	1
10	Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study 2023 ·Cancer Chemotherapy and Pharmacology ·Yuxiang Ma, Qun Chen, Yang Zhang, Jinhui Xue, Qianwen Liu, Yuanyuan Zhao, Yunpeng Yang, Yan Huang, Wenfeng Fang, Zhiguo Hou, Shaorong Li, Jing Wang, Li Zhang, (unknown)	1
11	Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation 2023 ·Nature Metabolism ·(unknown), (unknown), Zhixiang Dong, Yunpeng Yang, Jing Xing, (unknown), (unknown), Fengmei Xu, (unknown), (unknown), Xiangyang Guo, Qiang Sun, Guoping Zhao, Yang Gu, Guijun Qin, Weihong Jiang	23
12	Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors 2023 ·Journal for ImmunoTherapy of Cancer ·Yuxiang Ma, (unknown), Yuanyuan Zhao, Yang Zhang, Yan Huang, Yunpeng Yang, Wenfeng Fang, Ye Guo, Qun Li, Xiaoxiao Ge, (unknown), (unknown), Yuhan Zhang, (unknown), Li Zhang, Hongyun Zhao	34
13	A universal all-in-one RPA-Cas12a strategy with de novo autodesigner and its application in on-site ultrasensitive detection of DNA and RNA viruses 2023 ·Biosensors and Bioelectronics ·(unknown), Feng Chen, (unknown), (unknown), Changsheng He, (unknown), Xueping Li, Can Liu, (unknown), Yunpeng Yang, (unknown), (unknown), (unknown), Chenglai Xia, Zhibin Yan, Hongli Du, Lizhen Huang	34
14	FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer 2022 ·Clinical Cancer Research ·(unknown), Xi Chen, (unknown), Wen Xie, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Wei Zhuang, Shu Liu, Min Huang, Xueding Wang, Li Zhang	32
15	Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer 2020 ·Translational Oncology ·(unknown), Xi Chen, (unknown), Shu Liu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xia Zhu, Wei Zhuang, Fei Wang, (unknown), Xiaoxu Zhang, Min Huang, Xueding Wang, Li Zhang	11
16	LncRNA PVT1 Regulates TRPS1 Expression in Breast Cancer by Sponging miR-543 2020 ·SHILAP Revista de lepidopterología ·Hong Wang, Ya‐Hui Huang, Yunpeng Yang	2
17	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Shaodong Hong, Huaqiang Zhou, Ao Wang, Fufeng Wang, Hua Bao, Xue Wu, Yunpeng Yang, Yan Huang, Hongyun Zhao, Yang Shao, Li Zhang	139
18	Impact of preoperative exercise therapy on surgical outcomes in lung cancer patients with or without COPD: a systematic review and meta-analysis 2019 ·SHILAP Revista de lepidopterología ·Xi Li, Shaoping Li, Sheng Yan, Yipeng Wang, Xiang Wang, (unknown), Yunpeng Yang, (unknown)	0
19	The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706) 2019 ·Cancer Communications ·Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao	18
20	An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System 2014 ·Lung Cancer ·Yuxiang Ma, Yunpeng Yang, Yan Huang, Hongyun Zhao, Xue Hou, Ying Tian, Yuanyuan Zhao, Cong Xue, Wenfeng Fang, Xuan Wu, Zhihuang Hu, Wenhua Liang, Ting Zhou, Tao Qin, Li Zhang	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact